EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pushing the Boundaries of Biomarker Discovery in Phenylketonuria: Metabolomic Profiling Reveals Novel Biomarkers and Their Associations with Phenylalanine

Reem AlMalki, Shereen M Aleidi iD, Maha Al Mogren iD, Shaima Almohsen, Khalid M Sumaily iD, Ahmed Alfares iD, Anas M Abdel Rahman iD

Molecules · 08.06.2026 · 31 (12) · 2000

DOI: 10.3390/molecules31122000 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 08.06.2026. Verfasst von Reem AlMalki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Metabolomics Section, Precision Medicine Laboratory Department, Genomics Medicine Center of Excellence, King Faisal Specialist Hospital and Research …. Hauptthemen laut MEDLINE: Phenylketonurias, Biomarkers, Phenylalanine, Metabolomics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ongoing Research Funding Program, King Saud University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Phenylketonuria (PKU) is a rare genetic disorder caused by mutations in the phenylalanine hydroxylase (PAH) gene, resulting in a deficiency of the enzyme responsible for metabolizing phenylalanine (Phe) and its accumulation. PKU can be identified through newborn screening (NBS) or genetic sequencing; however, both approaches have limitations, including high false-discovery rates and variants of uncertain significance (VUS). This study aims to identify a PKU metabolomic profile using unique biomarkers to enhance early diagnosis and improve treatment outcomes.

Methods

Dried blood spot (DBS) samples from 65 patients diagnosed with PKU and matched healthy controls were collected through the NBS program. An untargeted metabolomics analysis was conducted using liquid chromatography-high-resolution mass spectrometry (LC-HRMS) to profile metabolites and investigate altered metabolic pathways in patients with PKU.

Results

A total of 418 significantly dysregulated metabolites were identified in PKU patients. Among them, 90 metabolites were identified as endogenous human metabolites. The most significantly affected pathways were those related to the metabolism of aromatic amino acids and polysaccharides. Moreover, lipid metabolic pathways were dysregulated, including those involved in fatty acid and phospholipid biosynthesis. In addition to phenylalanine (AUC = 0.994), 1,11-Undecanedicarboxylic acid (UDCA) (AUC = 0.969) was significantly elevated in patients with PKU, suggesting it is a promising potential biomarker for PKU.

Conclusions

Untargeted metabolomics revealed distinct metabolic alterations in patients with PKU, providing insights into disease pathophysiology. The identification of UDCA as a consistently elevated metabolite supports its potential utility as a supplementary biomarker for PKU diagnosis and monitoring. Further validation in larger cohorts, using a targeted metabolomics approach, is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenylketonuriasBiomarkersPhenylalanineMetabolomicsMetabolomeHumansFemaleMaleInfant, NewbornPhenylalanine HydroxylaseMetabolic Networks and PathwaysNeonatal Screening

Stichwörter der Autor:innen

biomarkernext-generation metabolic screening (NGMS)phenylalaninephenylketonuriauntargeted metabolomics

Substanzen

BiomarkersPhenylalaninePhenylalanine Hydroxylase

Autor:innen und Institutionen

  • Metabolomics Section, Precision Medicine Laboratory Department, Genomics Medicine Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
  • College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates.
  • Department of Biopharmaceutics and Clinical Pharmacy, School of Pharmacy, The University of Jordan, Amman 11942, Jordan.
  • Clinical Biochemistry Unit, Pathology Department, College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia.
  • Department of Neuroscience and Renal, Bristol Medical School, Dorothy Hodgkin Building, Whitson Street, Bristol BS1 3NY, UK.

ORCID-Profile: Shereen M Aleidi, Maha Al Mogren, Khalid M Sumaily, Ahmed Alfares, Anas M Abdel Rahman

Förderung

  • Ongoing Research Funding Program
  • King Saud University

Zitieren

APA

AlMalki, R., Aleidi, S. M., Al Mogren, M., Almohsen, S., Sumaily, K. M., Alfares, A., & Rahman, A. M. A. (2026). Pushing the Boundaries of Biomarker Discovery in Phenylketonuria: Metabolomic Profiling Reveals Novel Biomarkers and Their Associations with Phenylalanine. Molecules, 31(12), 2000. https://doi.org/10.3390/molecules31122000

Vancouver

AlMalki R, Aleidi SM, Al Mogren M, Almohsen S, Sumaily KM, Alfares A, et al. Pushing the Boundaries of Biomarker Discovery in Phenylketonuria: Metabolomic Profiling Reveals Novel Biomarkers and Their Associations with Phenylalanine. Molecules. 2026;31(12):2000. doi:10.3390/molecules31122000

BibTeX
@article{AlMalki2026,
  author = {AlMalki, Reem and Aleidi, Shereen M and Al Mogren, Maha and Almohsen, Shaima and Sumaily, Khalid M and Alfares, Ahmed and Rahman, Anas M Abdel},
  title = {Pushing the Boundaries of Biomarker Discovery in Phenylketonuria: Metabolomic Profiling Reveals Novel Biomarkers and Their Associations with Phenylalanine},
  journal = {Molecules},
  year = {2026},
  volume = {31},
  number = {12},
  pages = {2000},
  doi = {10.3390/molecules31122000}
}
Kostenlos starten →